{"entity":{"id":"nct05948813","kind":"trial","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","aka":[],"tldr":"A phase 2 trial of TY-9591 and Osimertinib in non-small-cell lung cancer and brain and spinal cord tumours, run by TYK Medicines, Inc, now recruiting.","summary":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases is a phase 2 interventional study registered as NCT05948813 by TYK Medicines, Inc, with 420 participants planned, started 2023-08-17 and due to reach its primary completion in 2025-12-15. Interventions recorded: TY-9591 and Osimertinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05948813","url":"https://clinicaltrials.gov/study/NCT05948813"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["ty-9591","osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05948813","phase":"2","setting":"A Phase II Study of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain Metastases","sponsor":"TYK Medicines, Inc","enrolled":420,"outcomes":[]},"route":"/trials/nct05948813/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"ty-9591","kind":"drug","name":"TY-9591","route":"/drugs/ty-9591/"}]}}